KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Recursion Pharmaceuticals' Non Operating Income rose 27148.19% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 2981.55%. This contributed to the annual value of $14.2 million for FY2024, which is 2072.27% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Non Operating Income of $10.0 million as of Q3 2025, which was up 27148.19% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Non Operating Income ranged from a high of $10.0 million in Q3 2025 and a low of -$11.3 million during Q1 2025
  • Over the past 5 years, Recursion Pharmaceuticals' median Non Operating Income value was $2.5 million (recorded in 2024), while the average stood at $2.0 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 22680000.0% in 2023, then crashed by 36926.93% in 2025.
  • Recursion Pharmaceuticals' Non Operating Income (Quarter) stood at $27000.0 in 2021, then skyrocketed by 12825.93% to $3.5 million in 2022, then plummeted by 46.36% to $1.9 million in 2023, then soared by 160.1% to $4.9 million in 2024, then surged by 104.4% to $10.0 million in 2025.
  • Its Non Operating Income was $10.0 million in Q3 2025, compared to $4.3 million in Q2 2025 and -$11.3 million in Q1 2025.